Pfizer files COVID-19 vaccine application to U.S. FDA
By Vishwadha Chander (Reuters) - Pfizer Inc applied to U.S. health regulators on Friday for emergency use authorization (EUA) of its COVID-19 vaccine, the first such application in a major step toward providing protection against the new coronavirus. The application to the U.S.
COVID-19 vaccine application to U.S. FDA" src="https://images.firstpost.com/wp-content/uploads/reuters/11-2020/21/2020-11-20T120659Z_2_LYNXMPEGAJ0N3_RTROPTP_2_HEALTH-CORONAVIRUS-EU-PFIZER.jpg" alt="Pfizer files COVID19 vaccine application to US FDA" width="300" height="225" />
By Vishwadha Chander
(Reuters) - Pfizer Inc
The application to the U.S. Food and Drug Administration (FDA) comes just days after Pfizer and German partner BioNTech SE <22UAy.DE>
Pfizer Chief Executive Officer Albert Bourla confirmed the application had been made in a video posted on the company's website on Friday afternoon.
Pfizer's shares were up 1.3% and BioNTech shares up 9.3% in New York late on Friday afternoon, as the possibility of a vaccine soon raised hopes for the end of a pandemic that has claimed more than a quarter of a million lives in the United States and over 1.3 million worldwide.
For an interactive graphic tracking the global spread of COVID-19 , open https://graphics.reuters.com/world-coronavirus-tracker-and-maps/ in an external browser.
The application also includes safety data on about 100 children 12-15 years of age. The company said 45% of U.S. trial participants are 56-85 years old.
If the data is solid, "we literally could be weeks away from the authorization of a 95% effective vaccine," U.S. Health and Human Services Secretary Alex Azar said on CBS's "This Morning."
The companies expect the FDA to grant the EUA by mid-December and said they will begin shipping doses almost immediately. Pfizer has said it expects to have 50 million vaccine doses ready this year, enough to protect 25 million people.
An FDA advisory committee tentatively plans to meet Dec. 8-10 to discuss the vaccine, a source familiar with the situation told Reuters, though the dates could change.
The final trial data showed the vaccine provided a similar level of protection across different ages and ethnicities - an encouraging result as the disease disproportionately hurts the elderly and minorities.
Of the 170 volunteers who contracted COVID-19 in Pfizer's trial involving over 43,000 people, 162 had received only a placebo, meaning the vaccine was 95% effective, far higher than originally expected. The U.S. FDA had set minimum bar for efficacy of 50%.
Pfizer said nearly 42% of global participants and 30% of U.S. participants in the Phase 3 study have racially and ethnically diverse backgrounds.
"Filing in the U.S. represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world and we now have a more complete picture of both the efficacy and safety profile of our vaccine," Bourla said in a statement.
Both the Pfizer/BioNTech and Moderna vaccines work using a new technology to trigger an immune response known as synthetic messenger RNA that can be produced at scale much more quickly than traditional vaccines.
Of dozens of drugmakers and research institutions racing to develop COVID-19 vaccines, the next late-stage data is expected to come from AstraZeneca Plc
Johnson & Johnson
(Reporting by Vishwadha Chander in Bengaluru, additional reporting by Ankur Banerjee in Bengaluru, Caroline Humer in New York and Doina Chiacu in Washington; Editing by Bill Berkrot and Matthew Lewis)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
By Chuck Mikolajczak NEW YORK (Reuters) - A gauge of global stocks hit a record and oil prices jumped on Monday as the newest positive data for a potential COVID-19 vaccine and signs of economic recovery in Asia boosted sentiment. U.S. stocks advanced, with the Dow Industrials setting a record as it neared the 30,000 mark for the first time, after pharma company Moderna said its prospective vaccine was 94.5% effective in preventing the illness, which has crushed economies across the globe
By Anirban Sen and Joshua Franklin (Reuters) - Airbnb Inc's initial public offering (IPO) registration showed on Monday that the home rental startup turned a profit in the third quarter despite the COVID-19 pandemic, as it gears up for one of the most anticipated stock market debuts in recent years. The filing, published ahead of Airbnb's anticipated stock market debut in December, showed a dramatic recovery in its fortunes, after the coronavirus outbreak dragged down its core home rental business during the first half of the year. The slump forced it to lay off 25% of its workforce in May, suspend marketing activities for the year and seek $2 billion (£1.5 billion) emergency funding from investors, including Silver Lake and Sixth Street Partners, at a valuation of $18 billion
By David Lawder WASHINGTON (Reuters) - U.S. President-elect Joe Biden said on Monday the United States needed to negotiate with allies to set global trading rules to counter China's growing influence but declined to say whether he would join a new China-backed Asian trade pact signed on Sunday.